panitumumab
Qiagen, Amgen Collaborate to Develop CDx for Investigational NSCLC Drug
The companies will develop tissue-based companion diagnostics for Amgen's investigational treatment AMG 510 for non-small cell lung cancer.
Biocartis, Amgen Sign CDx Development Deal for Idylla RAS Biomarker Tests
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
Illumina Receives FDA Approval for Companion Dx to Run on MiSeqDx
Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.